WA-T-MOBILE
Today, T-Mobile US (NASDAQ: TMUS) and Deutsche Telekom AG (NASDAQ: DTEGY) launched T-IoT, a comprehensive enterprise solution for global IoT connectivity, platform management and support. With T-IoT, enterprises have one global team and one global solution to manage all their connections across borders! And it will be available across 188 destinations, on 383 networks worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220220005042/en/
“The Un-carrier rewrote the rules of wireless. Now, as America’s 5G leader, with the fastest, largest, and most reliable 5G network, we’re writing the rules of the 5G era, and we’re doing it in favor of customers and businesses,” said Mike Katz, President, T-Mobile Business Group. “With T-IoT and our award-winning networks, we’re poised to help businesses realize the true potential of IoT by completely disrupting the status quo of how IoT is purchased and managed.”
Unleashing the Power of IoT
Despite all the excitement around IoT’s ability to make the connected world a reality, unlock valuable business insights, improve customer experience, cut operational costs, and boost efficiency—many enterprises haven’t fully captured value at scale from IoT. Why is this still happening in 2022? A major reason is that Carriers make enterprises jump through hoops to manage IoT connectivity globally. To deploy multinational IoT connections, enterprises have to cobble together a patchwork of operator agreements—all with different contracts, service level agreements, management interfaces, and customer support.
And 5G promises to take IoT to the next level, with cellular 5G IoT connections projected to make up 57 percent of all worldwide cellular IoT connections by 20251 . With 5G’s ability to support low-latency, massive data use, and connect up to 100x more devices than 4G—enterprises have a HUGE opportunity to embrace new use cases and actionable data that will make the longstanding vision of 5G IoT a reality.
But the gap between the promise of 5G IoT and reality will be wide if managing all that connectivity and data remains unnecessarily complex.
Here’s why: Imagine millions of tracked assets moving across the globe. To stay connected to those assets, enterprises have to negotiate numerous contracts with multiple network operators in different countries and regions, each with its own contract, and service level agreements. Then, to view and manage those devices, they navigate a multitude of platforms from various operators. And for every issue that arises, you can bet there are different customer care and support teams.
There’s also little flexibility in how enterprises pay for IoT. Each Carrier has its own payment model which makes it hard for businesses to effectively scale IoT across the globe. And with 5G, scaling will be even more important to deliver valuable use cases, analytics, data insight, and return-on-investment.
Enter T-IoT—a solution optimized for enterprises with global IoT needs
Today we say “goodbye” to that complex and rigid system because T-Mobile and Deutsche Telekom are coming together to disrupt the status quo with T-IoT. This one-of-a-kind global offering exemplifies two words rarely associated with IoT — simple and flexible.
T-IoT will deliver:
- Worldwide network connectivity spanning the full range of technologies to support nearly every possible IoT scenario today, and tomorrow—including NB-IoT, LTE-M, LTE, and 5G.
- A single pane of glass to easily view, and eventually manage global IoT connections across several platforms, including T-Mobile Control Center and Deutsche Telekom M2M Service Portal, with T-IoT Hub.
- A simplified procurement process that includes streamlined contract and billing, consistent global service level agreements, and customer support.
- Flexible pricing with a pay-per-data model OR a choice of three flat-rate unlimited connectivity packages (T-IoT Unlimited Base, T-IoT Unlimited Premium, and T-IoT Unlimited Pro) across the U.S. and Europe, as well as value added services to serve connectivity needs for the lifetime of the device.
"One provider. One solution. That's 'making it simple' taken at its word," says Hagen Rickmann, Managing Director Business Customers, Telekom Deutschland. "Many industries, such as healthcare or automotive, depend on international supply chains. And their customers today rely on receiving service and assistance anywhere in the world. We're able to do that with this transatlantic collaboration, with our networks, for the best customer experience worldwide."
“With millions of connected Mercedes-Benz vehicles in nearly every corner of the world today, and up to 20 million connected cars in our fleet by 2025, we need be able to rely on telecommunications partners like T-IoT, that offer us global network coverage and an ecosystem for IoT leadership,” said Ola Källenius, Chairman of the Board of Management, Mercedes-Benz Group AG. “Real-time, high-bandwidth data transmission is key to digital innovation. 5G technology in IoT scenarios will allow our vehicles to communicate with the speed and reliability needed to offer our customers greater efficiency through improved routing and improved safety.”
BIOTRONIK, a leading global medical device company based In Berlin, also relies on seamless connectivity. With their innovative, first-in-class Home Monitoring solution, many BIOTRONIK medical devices are connected devices, which help to significantly increase the quality of lives of millions each year. Patients can travel without worry as BIOTRONIK works with around 5,000 hospitals worldwide, which provide care in the event of an emergency at all times.
"We combine digital medical solutions and state-of-the-art communication technology. With Home Monitoring, the patient’s vital data is digitally available to the medical team and are constantly analyzed. If threshold values are exceeded, the medical team can react immediately," says Volker Lang, Senior Vice President Research and Development. "This only works with an absolutely reliable network that transmits the data reliably at all times. We are active in over 100 countries. The T-IoT infrastructure is indispensable for us.”
To learn more about T-IoT and get connected, visit https://www.t-mobile.com/business/t-iot .
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
Coverage not available in some areas. Some uses may require certain plan or feature; see T-Mobile.com. Most Reliable: According to an audit report conducted by independent third party umlaut containing crowdsourced data for user experience collected from April to September 2021. Full details at: www.umlaut.com/en/benchmarking/USA . Fastest: Based on median, overall combined 5G speeds according to analysis by Ookla® of Speedtest Intelligence® data 5G download speeds for Q4 2021. Ookla trademarks used under license and reprinted with permission.
About T-Mobile
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com .
1 IDC, Worldwide and U.S. IoT Cellular Connections Forecast, 2021–2025, Doc # US47296121, August 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20220220005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom